Analytical Data
-
Gene name
IL-2R alpha/CD25
- Application
-
Alternative Names
CD25; IL2R-a; IL2-RA; IDDM10; IL2R; TCGFR; p55; TAC antigen
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01590
-
Expression Region
Glu22~Tyr235
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-2R alpha, also known as CD25, is a key component of the interleukin-2 receptor complex and plays a critical role in the regulation of immune responses. It is predominantly expressed on activated T cells and regulatory T cells (Tregs), influencing their proliferation, survival, and function. Research into IL-2R alpha/CD25 has gained significant attention due to its implications in various immunological disorders, including autoimmune diseases, graft-versus-host disease, and cancer. Elevated levels of CD25 are often associated with a more aggressive tumor phenotype, while modulation of its expression can potentially enhance anti-tumor immunity. Recombinant forms of IL-2R alpha/CD25 are employed in both basic research and therapeutic applications, serving as potential biomarkers for immune activation and targets for immunotherapy. Studies have focused on characterizing the molecular mechanisms underlying CD25 expression and signaling pathways, as well as the development of CD25-targeted therapies, such as monoclonal antibodies. The exploration of IL-2R alpha/CD25 provides insights into T cell regulation, with the potential to enhance therapeutic strategies for immunological diseases and improve outcomes in cancer treatment. Given the ongoing advancements in biotechnology, the production of recombinant IL-2R alpha/CD25 offers a valuable tool for elucidating its functional roles and therapeutic potential within the immune system.
